
World class research today, superior patient care tomorrow
Academic excellence
As recognized leaders in pharmacogenomics (PGx), Dr. Broeckel and the RPRD research team are known for their scientific rigor and academic excellence. We partner with the world’s leading medical institutions to advance PGx research and practice.
View our academic publications and scientific contributions listed below that highlight our academic excellence and commitments in scientific and clinical research.

Selected Publications:
Charity, N, et al. PharmVar GeneReview: CYP2D6. Clin Pharmacol Ther. 2020. 107 (1) 154
Conference abstracts:
Performance Analysis of a Comprehensive Clinically Focused Pharmacogentic Assay
Presented at the Pharmacogenomics Research Network (PGRN) Meeting 2020
Aggarwal, P., Turner, A., Derezenski, A., Scharer, G., Broeckel, U.
Click here to download the poster
Pharmacogenomic Genotyping Performance Across Biological Specimens
Presented at the University of Minnesota Biennial Pharmacogenomics Conference 2020
Turner, A., Aggarwal, P., Scharer, G., Derezenski, A., Gaedigk, A., Broeckel, U.
Click here to download the poster
Characterization of CYP2D6 Structural Variants Containing the CYP2D6 *68 Hybrid
Turner, A, Nofziger, C, Boone, E, Scantamburlo, G, Vanoni, S, Haidar, C, Relling, M, Broeckel, U, Gaedigk, A.
Presented at the American Society of Human Genetics (ASHG) annual conference 2019
Identification of Novel CYP2D6 Haplotypes that Interfere with TaqMan Copy Number Analysis
Turner A, Aggarwal, P, Boone E, Haidar, C, Relling, M, Broeckel, U, Gaedigk, A.
Presented at the Clinical Pharmacogenetics Implementation Consortium (CPIC) meeting 2019
The PharmacoScanTM Array: Performance Across Biological Specimens
Turner, A, Aggarwal, P, Lorier, R, Gaedigk, A, Broeckel, U
Presented at the Clinical Pharmacogenetics Implementation Consortium (CPIC) meeting 2019
TPMT and NUDT15 Genotyping for Comprehensive Detection of Thiopurine Sensitivity in Multi-Ethnic Populations
Turner, A, Aggarwal, P, Lorier, R, Scharer, G, Broeckel, U.
Presented at the Clinical Pharmacogenetics Implementation Consortium (CPIC) meeting 2019
Four Novel NUDT15 Haplotypes Relevant for Treatment of Acute Lymphoblastic Leukemia
Turner A, Aggarwal P, Scharer G, Broeckel U.
Presented at The American Society of Pediatric Hematology/Oncology (ASPHO) 2019.
Click here to download poster.
Identification of Novel CYP2D6 Haplotypes that Interfere with TaqMan Copy Number Analysis
Turner A, Aggarwal P, Boone EC, Haidar CE, Relling M., Broeckel U, Gaedig, A.
Presented at American Society of Human Genetics (ASHG) 2018.
Click here to download poster.
Implementation of Affymetrix PharmacoScanTM for Comprehensive Preemptive Clinical Pharmacogenetic Testing
Turner A, Lorier R, Aggarwal, P Matter A, Broeckel U.
Presented at American Society of Human Genetics (ASHG) 2016.

Our additional contributions to PGx development
Clinical Pharmacogenetics Implementation Consortium (CPIC):
Drs. Broeckel (CEO and founder) and Scharer (CMO) are both long-standing members of the CPIC® since its inception in 2009. CPIC is a pioneering PGx consortium committed to facilitating the implementation of PGx testing in the clinic by providing actionable clinical guidelines to translate genetic tests results into customized patient-focused prescribing decisions by physicians for certain drugs. The detailed evidence-based, gene/drug clinical recommendations created by CPIC are peer-reviewed and are being increasingly used in the clinical practice. They are regarded as the standard guideline in PGx clinical implementation.
Read more about CPIC.
PharmVar
Amy Turner (Director of Research and Development) is a member of the Pharmacogene Variation (PharmVar) Consortium and serves as a gene expert for CYP2D6, NUDT15, and DPYD.
PharmVar was established in 2018 and funded by the Pharmacogenomics Research Network (PGRN) to serve as repository for PGx gene data and its nomenclature. PharmVar aims to facilitate and develop a standardized PGx gene nomenclature for the entire global PGx community.
Amy Turner’s contribution to the PharmVar NUDT15 gene introduction:
Amy Turner’s contribution to the PharmVar Gene Review CYP2D6
Charity, N. et al. PharmVar GeneReview: CYP2D6. Clin Pharmacol Ther. 2019 Sep [ePub ahead].
Read more about PharmVar.
Genetic Testing Reference Materials Coordination Program (GeT-RM)
Dr. Broeckel and his research team have been an important contributor to the GeT-RM since 2015. As part of the Clinical Laboratory Improvement Amendments (CLIA) regulations of 1988, the Get-RM program is supported by the Centers for Disease Control and Prevention (CDC). The goal of the GeT-RM is to establish a PGx community dedicated to creating reference materials, quality control measures, and proficiency testing for genetic testing.
Dr. Broeckel’s team has characterized the PGx impact of genomic DNA reference materials utilizing the PharmacoScanTM and its predecessor DMET platform.
Read more about Get-RM program.

Collaborating Opportunities
As a team primarily driven by passion for science, we are excited to work with the bright minds in the precision medicine community. If you are interested in collaborating with RPRD, please contact us to discuss potential opportunities.
Improve Drug R&D
Pharmacogenetics testing is an increasingly important tool to mitigate risks for clinical trials, interpretation of clinical data and retrospective studies.
Improve Patient Outcomes
Through our continued research in advanced PGx technologies and solutions, we help clinicians practice personalized medicine to achieve better outcomes for their patients.